Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BelaRd: Belantamab Mafodotin + Len/Dex in NDMM
NCT04808037Phase 2Active, not recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2021
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Started Feb 2021; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04808037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808037.